{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T14:09:08Z","timestamp":1793542148326,"version":"4.5.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2024.49453","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T16:31:15Z","timestamp":1733502675000},"page":"e2449453","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacogenomics in Oncology\u2014Running Out of Excuses for Slow Adoption"],"prefix":"10.1001","volume":"7","author":[{"given":"Howard L.","family":"McLeod","sequence":"first","affiliation":[{"name":"Center for Precision Medicine, Utah Tech University, St George"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Grace","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Cancer Pharmacology and Pharmacogenomics, Atrium Health Levine Cancer Institute, Charlotte, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"zic240313r1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejca.2021.12.009","article-title":"UGT1A1 genotype-guided dosing of irinotecan: a prospective safety and cost analysis in poor metaboliser patients.","volume":"162","author":"Hulshof","year":"2022","journal-title":"Eur J Cancer"},{"issue":"35","key":"zic240313r2","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1200\/JCO.22.02780","article-title":"Survival of patients with cancer with DPYD variant alleles and dose-individualized fluoropyrimidine therapy-a matched-pair analysis.","volume":"41","author":"Knikman","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"zic240313r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.21290","article-title":"Evaluation of the association of perioperative UGT1A1 genotype-dosed FOLFIRINOX with margin-negative resection rates and pathologic response grades among patients with locally advanced gastroesophageal adenocarcinoma: a phase 2 clinical trial.","volume":"3","author":"Catenacci","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"15","key":"zic240313r4","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1200\/JCO.22.02364","article-title":"DPYD testing: time to put patient safety first.","volume":"41","author":"Baker","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"zic240313r5","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1200\/OP.23.00776","article-title":"Design and implementation of an opt-out, end-to-end, preemptive DPYD testing program for patients planned for a systemic fluoropyrimidine.","volume":"20","author":"Jacobson","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"zic240313r6","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00623","article-title":"Real-world impact of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test on fluoropyrimidine dosing, toxicities, and hospitalizations at a multisite cancer center.","volume":"8","author":"Nguyen","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"zic240313r7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"zic240313r8","article-title":"Clinical benefits and utility of pretherapeutic DPYD and UGT1A1 testing in gastrointestinal cancer: a secondary analysis of the PREPARE randomized clinical trial.","volume":"7","author":"Roncato","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"10374","key":"zic240313r9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"zic240313r10","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1634\/theoncologist.2017-0599","article-title":"Value of supportive care pharmacogenomics in oncology practice.","volume":"23","author":"Patel","year":"2018","journal-title":"Oncologist"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2827569\/mcleod_2024_ic_240313_1732642092.1086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T16:31:17Z","timestamp":1733502677000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2827569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.49453","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]}}}